Abstract
In the standard corticotropin-stimulation test, which is used to assess the function of the hypothalamo–pituitary–adrenal axis, synthetic corticotropin is administered at a dose of 250 µg. Previous studies suggested that tests that use lower corticotropin doses had better discrimination than standard-dose tests possibly by avoiding supraphysiological concentrations of corticotropin. Here, we discuss a meta-analysis by Kazluaskaite et al. that compared standard-dose and low-dose corticotropin-stimulation tests and concluded that the low-dose test has a superior sensitivity and specificity. Superiority over the standard-dose test, however, was only found following a series of internal corrections and adjustments conducted by the investigators that might be inappropriate. Unadjusted meta-analyses demonstrated no advantage of the low-dose test over the standard-dose test. As data on the long-term follow-up of patients with borderline results are only available for the standard 250 µg dose test, this test should continue to be advocated, with assay-specific cut-off levels.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Nature Clinical Practice Endocrinology & Metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
